Table of Contents Author Guidelines Submit a Manuscript
Advances in Public Health
Volume 2016 (2016), Article ID 6254157, 8 pages
http://dx.doi.org/10.1155/2016/6254157
Research Article

Public Awareness and Identification of Counterfeit Drugs in Tanzania: A View on Antimalarial Drugs

1Institute of Allied Sciences, Catholic University of Health and Allied Sciences, Mwanza, Tanzania
2School of Pharmacy, Catholic University of Health and Allied Sciences, Mwanza, Tanzania
3Department of Pharmacology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania

Received 20 February 2016; Revised 9 May 2016; Accepted 17 May 2016

Academic Editor: Ronald J. Prineas

Copyright © 2016 Linus Mhando et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Clift, Combating Counterfeit, Falsified and Substandard Medicines: Defining the Way Forward?Chatham House, London, UK, 2010.
  2. WHO, Counterfeit and Substandard Drugs in Myanmar and Vietnam, World Health Organization, Geneva, Switzerland, 1999.
  3. P. N. Newton, M. D. Green, and F. M. Fernández, “Impact of poor-quality medicines in the ‘developing’ world,” Trends in Pharmacological Sciences, vol. 31, no. 3, pp. 99–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Hamelin, S. Nwankwo, and R. El Hadouchi, “'Faking brands': consumer responses to counterfeiting,” Journal of Consumer Behaviour, vol. 12, no. 3, pp. 159–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Cockburn, P. N. Newton, E. K. Agyarko, D. Akunyili, and N. J. White, “The global threat of counterfeit drugs: why industry and governments must communicate the dangers,” PLoS Medicine, vol. 2, no. 4, article 302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Almuzaini, I. Choonara, and H. Sammons, “Substandard and counterfeit medicines: a systematic review of the literature,” BMJ Open, vol. 3, no. 8, Article ID e002923, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Schlagenhauf and E. Petersen, “Antimalaria drug resistance: the mono–combi–counterfeit triangle,” Expert Review of Anti-Infective Therapy, vol. 7, no. 9, pp. 1039–1042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. B. D. Glass, “Counterfeit drugs and medical devices in developing countries,” Research and Reports in Tropical Medicine, vol. 2014, no. 5, pp. 11–22, 2014. View at Publisher · View at Google Scholar
  9. R. Bate and K. Boateng, “Bad medicine in the market,” World Hospitals and Health Services, vol. 43, no. 3, pp. 17–21, 2007. View at Google Scholar
  10. D. K. Mali, S. S. Mitkare, R. S. Moon, and R. Kshirsagar, “Anti-counterfeit packaging in pharma industry: review,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 3, article 46, 2011. View at Google Scholar · View at Scopus
  11. D. N. Akunyili, “Counterfeit drugs and pharmacovigilance,” in Proceedings of the 10th Pharmacovigilance Training Course held at Uppsala Monitoring Centre, Uppsala, Sweden, May 2005.
  12. P. N. Newton, M. D. Green, F. M. Fernández, N. P. Day, and N. J. White, “Counterfeit anti-infective drugs,” Lancet Infectious Diseases, vol. 6, no. 9, pp. 602–613, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. I. Wertheimer, N. M. Chaney, and T. Santella, “Counterfeit pharmaceuticals: current status and future projections,” Journal of the American Pharmacists Association, vol. 43, no. 6, pp. 710–718, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Tadeg and Y. Berhane, “Substandard and counterfeit antimicrobials: recent trends and implications to key public health interventions in developing countries,” East African Journal of Public Health, vol. 9, no. 2, pp. 85–89, 2012. View at Google Scholar · View at Scopus
  15. A. Khan and N. Ghilzai, “Counterfeit and substandard quality of drugs: the need for an effective and stringent regulatory control in India and other developing countries,” Indian Journal of Pharmacology, vol. 39, no. 4, pp. 206–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Burns, “WHO launches taskforce to fight counterfeit drugs,” Bulletin of the World Health Organization, vol. 84, no. 9, pp. 689–690, 2006. View at Google Scholar · View at Scopus
  17. O. Chinwendu, The Fight against Fake Drugs by NAFDAC in Nigeria, Royal Tropical Institute (KIT), Amsterdam, The Netherlands, 2008.
  18. C. S. Gautam, A. Utreja, and G. L. Singal, “Spurious and counterfeit drugs: a growing industry in the developing world,” Postgraduate Medical Journal, vol. 85, no. 1003, pp. 251–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. I. Wertheimer and J. Norris, “Safeguarding against substandard/counterfeit drugs: mitigating a macroeconomic pandemic,” Research in Social and Administrative Pharmacy, vol. 5, no. 1, pp. 4–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Dondorp, P. N. Newton, M. Mayxay et al., “Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials,” Tropical Medicine and International Health, vol. 9, no. 12, pp. 1241–1246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. S. E. Nsimba, “Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy,” East African Journal of Public Health, vol. 5, no. 3, pp. 205–210, 2009. View at Google Scholar
  22. T. Kelesidis, I. Kelesidis, P. I. Rafailidis, and M. E. Falagas, “Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 2, pp. 214–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Cordina, Counterfeit medicines.
  24. J. Wilson and R. Fenoff, “The health and economic effects of counterfeit pharmaceuticals in Africa,” globalEDGE Business Review, vol. 5, no. 6, pp. 1–2, 2011. View at Google Scholar
  25. B. Waka, Response Strategies of Haco Industries Kenya Limited to the Challenges of Counterfeit Products in East Africa, University of Nairobi, 2007.
  26. L. Meeking, “Counterfeit economy: the impacts of counterfeit goods on African society: Africa-wide-featured analysis,” Africa Conflict Monthly Monitor, pp. 8–12, 2013. View at Google Scholar
  27. P. Aldhous, “Counterfeit pharmaceuticals: murder by medicine,” Nature, vol. 434, no. 7030, pp. 132–136, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Akunyili, “Fake and counterfeit drugs in the health sector: the role of medical doctors,” Annals of Ibadan Postgraduate Medicine, vol. 2, no. 2, pp. 19–23, 2004. View at Publisher · View at Google Scholar
  29. K. Karunamoorthi, “The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence,” Malaria Journal, vol. 13, no. 1, article 209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. P. N. Newton, N. J. White, J. A. Rozendaal, and M. D. Green, “Murder by fake drugs: time for international action,” British Medical Journal, vol. 324, no. 7341, pp. 800–801, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Newton, S. Proux, M. Green et al., “Fake artesunate in southeast Asia,” The Lancet, vol. 357, no. 9272, pp. 1948–1950, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. G. M. L. Nayyar, J. G. Breman, P. N. Newton, and J. Herrington, “Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa,” The Lancet Infectious Diseases, vol. 12, no. 6, pp. 488–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Bate, P. Coticelli, R. Tren, and A. Attaran, “Antimalarial drug quality in the most severely malarious parts of Africa—A Six Country Study,” PLoS ONE, vol. 3, no. 5, article e2132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Kerb, R. Fux, K. Mörike et al., “Pharmacogenetics of antimalarial drugs: effect on metabolism and transport,” The Lancet Infectious Diseases, vol. 9, no. 12, pp. 760–774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Blessborn, S. Römsing, A. Annerberg et al., “Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper,” Journal of Pharmaceutical and Biomedical Analysis, vol. 45, no. 2, pp. 282–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Onwujekwe, H. Kaur, N. Dike et al., “Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria,” Malaria Journal, vol. 8, no. 1, article 22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Mullaicharam, “Counterfeit herbal medicine,” International Journal of Nutrition, Pharmacology, Neurological Diseases, vol. 1, no. 2, pp. 97–102, 2011. View at Publisher · View at Google Scholar
  38. M. Björkman-Nyqvist, J. Svensson, and D. Yanagizawa, Can Good Products Drive Out Bad?: Evidence from Local Markets for (Fake?) Antimalarial Medicine in Uganda, Centre for Economic Policy Research, 2012.
  39. N. Siva, “Tackling the booming trade in counterfeit drugs,” The Lancet, vol. 376, no. 9754, pp. 1725–1726, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. P. N. Newton, R. McGready, F. Fernandez et al., “Manslaughter by fake artesunate in Asia—will Africa be next?” PLoS Medicine, vol. 3, no. 6, article e197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Bansal, S. Malla, K. Gudala, and P. Tiwari, “Anti-counterfeit technologies: a pharmaceutical industry perspective,” Scientia Pharmaceutica, vol. 81, no. 1, pp. 1–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. G. J. Buckley and L. O. Gostin, Causes of Falsified and Substandard Drugs, 2013.
  43. R. Koh, E. W. Schuster, I. Chackrabarti, and A. Bellman, “Securing the pharmaceutical supply chain,” White Paper, Auto-ID Labs, Massachusetts Institute of Technology, 2003. View at Google Scholar
  44. D. Bagozzi, Counterfeit Medicines: Fact Sheet N° 275, World Health Organization, 2006.
  45. K. M. Lybecker, “Rx Roulette: combatting counterfeit pharmaceuticals in developing nations,” Managerial and Decision Economics, vol. 28, no. 4-5, pp. 509–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. WHO, Guidelines for the Development of Measures to Combat Counterfeit Drugs, World Health Organization, Geneva, Switzerland, 1999.
  47. K. Dégardin, Y. Roggo, and P. Margot, “Understanding and fighting the medicine counterfeit market,” Journal of Pharmaceutical and Biomedical Analysis, vol. 87, pp. 167–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. E. A. Blackstone, J. P. Fuhr Jr., and S. Pociask, “The health and economic effects of counterfeit drugs,” American Health and Drug Benefits, vol. 7, no. 4, pp. 216–224, 2014. View at Google Scholar · View at Scopus
  49. D. Akunyili, “Counterfeiting medicines: a serious crime against humanity,” in Proceedings of the Director General of the National Agency for Food and Drug Administration and Control (NAFDAC '07), vol. 10, pp. 1–7, April 2007.
  50. A. Chika, S. O. Bello, A. O. Jimoh, and M. T. Umar, “The menace of fake drugs: consequences, causes and possible solutions,” Research Journal of Medical Sciences, vol. 5, no. 5, pp. 257–261, 2011. View at Publisher · View at Google Scholar · View at Scopus